Effects of restricting levothyroxine dosage strength availability

Kenneth B. Ain, Frank Pucino, Gyorgy Csako, Robert A. Wesley, Jan A. Drass, Charles Clark, Paul Ketteridge, Keith Crawford, Steve M. Banks, Thomas E. Dorworth

Research output: Contribution to journalArticle

Abstract

We conducted a prospective, randomized, controlled trial to assess whether hospital formulary restrictions involving limiting dosage strengths of levothyroxine affect physicians' ability to manage patients effectively and provide pharmacy cost savings in a tertiary care federal government research hospital. Thirty-three endocrinologists were randomly assigned to prescribe levothyroxine from a restrictive (dosage strengths of 25, 50, 100, 125, and 150 μg) or a nonrestrictive (dosage strengths of 25, 50, 75, 100, 112, 125, 150, 175, 200, and 300 μg) formulary through a central computer system. Their 241 respective outpatients' laboratory results and drug compliance were outcome measures. Achievement of treatment objectives was measured by thyroid function tests (free and total thyroxine, total triiodothyronine, thyrotropin), number of clinic visits, and compliance (survey method). Additional measures were drug distribution patterns, drug costs, and pharmacy inventory costs. Restriction of levothyroxine's dosage strength did not significantly alter therapeutic outcomes. However, the restricted formulary was associated with more complex dosing regimens, and resulted in no significant cost savings. It is not known whether such restriction would adversely affect the care of patients of nonspecialists. Prospective studies are required to verify presumed cost-containment measures before such measures are adopted for widespread application.

Original languageEnglish (US)
Pages (from-to)1103-1110
Number of pages8
JournalPharmacotherapy
Volume16
Issue number6 I
StatePublished - Nov 1996
Externally publishedYes

Fingerprint

Thyroxine
Formularies
Cost Savings
Hospital Formularies
Thyroid Function Tests
Costs and Cost Analysis
Federal Government
Drug Costs
Aptitude
Cost Control
Computer Systems
Triiodothyronine
Thyrotropin
Tertiary Healthcare
Ambulatory Care
Pharmaceutical Preparations
Compliance
Patient Care
Outpatients
Randomized Controlled Trials

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Ain, K. B., Pucino, F., Csako, G., Wesley, R. A., Drass, J. A., Clark, C., ... Dorworth, T. E. (1996). Effects of restricting levothyroxine dosage strength availability. Pharmacotherapy, 16(6 I), 1103-1110.

Effects of restricting levothyroxine dosage strength availability. / Ain, Kenneth B.; Pucino, Frank; Csako, Gyorgy; Wesley, Robert A.; Drass, Jan A.; Clark, Charles; Ketteridge, Paul; Crawford, Keith; Banks, Steve M.; Dorworth, Thomas E.

In: Pharmacotherapy, Vol. 16, No. 6 I, 11.1996, p. 1103-1110.

Research output: Contribution to journalArticle

Ain, KB, Pucino, F, Csako, G, Wesley, RA, Drass, JA, Clark, C, Ketteridge, P, Crawford, K, Banks, SM & Dorworth, TE 1996, 'Effects of restricting levothyroxine dosage strength availability', Pharmacotherapy, vol. 16, no. 6 I, pp. 1103-1110.
Ain KB, Pucino F, Csako G, Wesley RA, Drass JA, Clark C et al. Effects of restricting levothyroxine dosage strength availability. Pharmacotherapy. 1996 Nov;16(6 I):1103-1110.
Ain, Kenneth B. ; Pucino, Frank ; Csako, Gyorgy ; Wesley, Robert A. ; Drass, Jan A. ; Clark, Charles ; Ketteridge, Paul ; Crawford, Keith ; Banks, Steve M. ; Dorworth, Thomas E. / Effects of restricting levothyroxine dosage strength availability. In: Pharmacotherapy. 1996 ; Vol. 16, No. 6 I. pp. 1103-1110.
@article{aabcf27ac00d442f88daa63801bc7bff,
title = "Effects of restricting levothyroxine dosage strength availability",
abstract = "We conducted a prospective, randomized, controlled trial to assess whether hospital formulary restrictions involving limiting dosage strengths of levothyroxine affect physicians' ability to manage patients effectively and provide pharmacy cost savings in a tertiary care federal government research hospital. Thirty-three endocrinologists were randomly assigned to prescribe levothyroxine from a restrictive (dosage strengths of 25, 50, 100, 125, and 150 μg) or a nonrestrictive (dosage strengths of 25, 50, 75, 100, 112, 125, 150, 175, 200, and 300 μg) formulary through a central computer system. Their 241 respective outpatients' laboratory results and drug compliance were outcome measures. Achievement of treatment objectives was measured by thyroid function tests (free and total thyroxine, total triiodothyronine, thyrotropin), number of clinic visits, and compliance (survey method). Additional measures were drug distribution patterns, drug costs, and pharmacy inventory costs. Restriction of levothyroxine's dosage strength did not significantly alter therapeutic outcomes. However, the restricted formulary was associated with more complex dosing regimens, and resulted in no significant cost savings. It is not known whether such restriction would adversely affect the care of patients of nonspecialists. Prospective studies are required to verify presumed cost-containment measures before such measures are adopted for widespread application.",
author = "Ain, {Kenneth B.} and Frank Pucino and Gyorgy Csako and Wesley, {Robert A.} and Drass, {Jan A.} and Charles Clark and Paul Ketteridge and Keith Crawford and Banks, {Steve M.} and Dorworth, {Thomas E.}",
year = "1996",
month = "11",
language = "English (US)",
volume = "16",
pages = "1103--1110",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "6 I",

}

TY - JOUR

T1 - Effects of restricting levothyroxine dosage strength availability

AU - Ain, Kenneth B.

AU - Pucino, Frank

AU - Csako, Gyorgy

AU - Wesley, Robert A.

AU - Drass, Jan A.

AU - Clark, Charles

AU - Ketteridge, Paul

AU - Crawford, Keith

AU - Banks, Steve M.

AU - Dorworth, Thomas E.

PY - 1996/11

Y1 - 1996/11

N2 - We conducted a prospective, randomized, controlled trial to assess whether hospital formulary restrictions involving limiting dosage strengths of levothyroxine affect physicians' ability to manage patients effectively and provide pharmacy cost savings in a tertiary care federal government research hospital. Thirty-three endocrinologists were randomly assigned to prescribe levothyroxine from a restrictive (dosage strengths of 25, 50, 100, 125, and 150 μg) or a nonrestrictive (dosage strengths of 25, 50, 75, 100, 112, 125, 150, 175, 200, and 300 μg) formulary through a central computer system. Their 241 respective outpatients' laboratory results and drug compliance were outcome measures. Achievement of treatment objectives was measured by thyroid function tests (free and total thyroxine, total triiodothyronine, thyrotropin), number of clinic visits, and compliance (survey method). Additional measures were drug distribution patterns, drug costs, and pharmacy inventory costs. Restriction of levothyroxine's dosage strength did not significantly alter therapeutic outcomes. However, the restricted formulary was associated with more complex dosing regimens, and resulted in no significant cost savings. It is not known whether such restriction would adversely affect the care of patients of nonspecialists. Prospective studies are required to verify presumed cost-containment measures before such measures are adopted for widespread application.

AB - We conducted a prospective, randomized, controlled trial to assess whether hospital formulary restrictions involving limiting dosage strengths of levothyroxine affect physicians' ability to manage patients effectively and provide pharmacy cost savings in a tertiary care federal government research hospital. Thirty-three endocrinologists were randomly assigned to prescribe levothyroxine from a restrictive (dosage strengths of 25, 50, 100, 125, and 150 μg) or a nonrestrictive (dosage strengths of 25, 50, 75, 100, 112, 125, 150, 175, 200, and 300 μg) formulary through a central computer system. Their 241 respective outpatients' laboratory results and drug compliance were outcome measures. Achievement of treatment objectives was measured by thyroid function tests (free and total thyroxine, total triiodothyronine, thyrotropin), number of clinic visits, and compliance (survey method). Additional measures were drug distribution patterns, drug costs, and pharmacy inventory costs. Restriction of levothyroxine's dosage strength did not significantly alter therapeutic outcomes. However, the restricted formulary was associated with more complex dosing regimens, and resulted in no significant cost savings. It is not known whether such restriction would adversely affect the care of patients of nonspecialists. Prospective studies are required to verify presumed cost-containment measures before such measures are adopted for widespread application.

UR - http://www.scopus.com/inward/record.url?scp=10544228948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10544228948&partnerID=8YFLogxK

M3 - Article

C2 - 8947984

AN - SCOPUS:10544228948

VL - 16

SP - 1103

EP - 1110

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 6 I

ER -